Market Overview:
The global meningococcal disease treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of meningococcal disease, rising demand for meningococcal vaccines and antibiotics, and growing awareness about meningococcal disease. However, the high cost of MenB vaccines may restrain the growth of this market to some extent. Based on type, the global meningococcal disease treatment market can be segmented into antibiotics and vaccines. The antibiotics segment is expected to account for a larger share of this market than the vaccine segment during the forecast period. This can be attributed to factors such as rising incidence of bacterial infections and increasing demand for effective antibiotic therapies against these infections. However, development of novel vaccine candidates is anticipated to boost growth in the vaccine segment over the next few years. Based on application, hospitals are estimated to account for a larger share of this market than drugstores during 2018-2030 owing higher adoption rates for both antibiotics.
Product Definition:
Meningococcal disease is a serious infection caused by the bacterium Neisseria meningitidis. The bacteria can cause meningitis (infection of the membranes surrounding the brain and spinal cord) and/or sepsis (bloodstream infection). Meningococcal disease often leads to death, even with treatment. Treatment for meningococcal disease includes antibiotics and aggressive supportive care in a hospital setting.
Antibiotics:
Antibiotics Market Size, Share & Trends Analysis Report By Product (Penicillin, Cephalosporin), By Application (Meningitis Treatment, Endocarditis Treatment), And Segment Forecasts, 2019 - 2026 -> The global antibiotics market size was valued at USD 21.8 billion in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 3.0% from 2019 to 2026.
Vaccines:
Vaccines are biological agents used to stimulate the body's immune system to act against a disease-causing microorganism. There are two types of vaccines: attenuated and inactivated. Attenuated vaccines contain active ingredients that help fight off diseases like measles, mumps, and rubella (MMR).
Application Insights:
Based on the application, the global meningococcal disease treatment market is segmented into hospitals, drugstores and others. The hospitals segment dominated the overall market in terms of revenue in 2017 due to factors such as high patient admissions and deaths caused by meningococcal diseases. In addition, a large number of research studies have been conducted at Hospitals that involved patients suffering from meningococcal infections which further increased hospital dominance over other locations.
The drugstores segment is expected to grow at a lucrative rate during the forecast period owing to increasing awareness about vaccination against Meningitis among consumers globally coupled with rising incidences of Neisseria menigitica infection among humans worldwide.
Regional Analysis:
North America dominated the global meningococcal disease treatment market in 2017. This is due to the presence of a large number of players in this region, increased awareness about vaccination programs, and availability of advanced healthcare facilities. Moreover, increasing travel and trade activities across the globe are likely to boost demand for anti-infective drugs in North America over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising disposable income levels and improving healthcare infrastructure coupled with growing awareness about various available treatments for Meningococcal Disease (MD). Furthermore, high prevalence of Neisseria meningitidis infections among adolescents & young adults along with rapid urbanization & industrialization are some other factors that can be attributed towards regional market growth during the estimated time frame.
Growth Factors:
- Increasing incidence of meningococcal disease
- Rising demand for meningococcal vaccines
- Growing awareness about the benefits of early diagnosis and treatment of meningococcal disease
- Technological advancements in the field of meningococcal disease treatment
- increasing funding for research and development activities in the field of meningococcal disease
Scope Of The Report
Report Attributes
Report Details
Report Title
Meningococcal Disease Treatment Market Research Report
By Type
Antibiotics, Vaccines
By Application
Hospitals, Drugstores, Others
By Companies
Pfizer, GlaxoSmithKline, Sanofi Pasteur, NovartisÂ
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Meningococcal Disease Treatment Market Report Segments:
The global Meningococcal Disease Treatment market is segmented on the basis of:
Types
Antibiotics, Vaccines
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Drugstores, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- GlaxoSmithKline
- Sanofi Pasteur
- NovartisÂ
Highlights of The Meningococcal Disease Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antibiotics
- Vaccines
- By Application:
- Hospitals
- Drugstores
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Meningococcal Disease Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Meningococcal disease is a serious bacterial infection that can lead to meningitis, a potentially life-threatening condition. Treatment typically includes antibiotics and, in some cases, surgery.
Some of the key players operating in the meningococcal disease treatment market are Pfizer, GlaxoSmithKline, Sanofi Pasteur, Novartis‚Â .
The meningococcal disease treatment market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Meningococcal Disease Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Meningococcal Disease Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Meningococcal Disease Treatment Market - Supply Chain
4.5. Global Meningococcal Disease Treatment Market Forecast
4.5.1. Meningococcal Disease Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Meningococcal Disease Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Meningococcal Disease Treatment Market Absolute $ Opportunity
5. Global Meningococcal Disease Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Meningococcal Disease Treatment Market Size and Volume Forecast by Type
5.3.1. Antibiotics
5.3.2. Vaccines
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Meningococcal Disease Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Meningococcal Disease Treatment Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Drugstores
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Meningococcal Disease Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Meningococcal Disease Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Meningococcal Disease Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Meningococcal Disease Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Meningococcal Disease Treatment Demand Share Forecast, 2019-2026
9. North America Meningococcal Disease Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Meningococcal Disease Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Meningococcal Disease Treatment Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Drugstores
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Meningococcal Disease Treatment Market Size and Volume Forecast by Type
9.7.1. Antibiotics
9.7.2. Vaccines
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Meningococcal Disease Treatment Demand Share Forecast, 2019-2026
10. Latin America Meningococcal Disease Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Meningococcal Disease Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Meningococcal Disease Treatment Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Drugstores
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Meningococcal Disease Treatment Market Size and Volume Forecast by Type
10.7.1. Antibiotics
10.7.2. Vaccines
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Meningococcal Disease Treatment Demand Share Forecast, 2019-2026
11. Europe Meningococcal Disease Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Meningococcal Disease Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Meningococcal Disease Treatment Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Drugstores
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Meningococcal Disease Treatment Market Size and Volume Forecast by Type
11.7.1. Antibiotics
11.7.2. Vaccines
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Meningococcal Disease Treatment Demand Share, 2019-2026
12. Asia Pacific Meningococcal Disease Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Meningococcal Disease Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Meningococcal Disease Treatment Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Drugstores
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Meningococcal Disease Treatment Market Size and Volume Forecast by Type
12.7.1. Antibiotics
12.7.2. Vaccines
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Meningococcal Disease Treatment Demand Share, 2019-2026
13. Middle East & Africa Meningococcal Disease Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Meningococcal Disease Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Meningococcal Disease Treatment Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Drugstores
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Meningococcal Disease Treatment Market Size and Volume Forecast by Type
13.7.1. Antibiotics
13.7.2. Vaccines
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Meningococcal Disease Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Meningococcal Disease Treatment Market: Market Share Analysis
14.2. Meningococcal Disease Treatment Distributors and Customers
14.3. Meningococcal Disease Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GlaxoSmithKline
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sanofi Pasteur
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook